Positive results from Phase III EMPACTA RCT of tocilizumab treatment of hospitalised adults with COVID-19 meets primary endpoint

RCT in 389 patients with COVID-19 associated pneumonia found those who received tocilizumab plus standard of care were 44% less likely to progress to mechanical ventilation or death vs placebo plus standard of care (12.2% vs 19.3%; HR, 0.56; 95% CI, 0.32, 0.97; p= 0.0348).


Biospace Inc.